Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.

Suppr

超能文献

作者信息

Edmonson J H, Decker D G, Malkasian G D, Webb M J, Jorgensen E O

出版信息

Gynecol Oncol. 1978 Feb;6(1):7-9. doi: 10.1016/0090-8258(78)90002-1.

DOI:10.1016/0090-8258(78)90002-1

PMID:620951

Abstract

摘要

相似文献

Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.

Gynecol Oncol. 1978 Feb;6(1):7-9. doi: 10.1016/0090-8258(78)90002-1.

Phase II clinical trial of VP-16-213 in ovarian cancer.VP-16-213治疗卵巢癌的II期临床试验。

Cancer Treat Rep. 1981 Mar-Apr;65(3-4):329-30.

Phase II trial of VP-16-213 in advanced ovarian carcinoma.

Gynecol Oncol. 1985 Oct;22(2):162-6. doi: 10.1016/0090-8258(85)90022-8.

A combination of cyclophosphamide, methotrexate, vincristine and VP 16-213 (NSC 141 540) in the treatment of bronchogenic carcinoma.

Tumori. 1977 Mar-Apr;63(2):169-73. doi: 10.1177/030089167706300207.

Phase II evaluation of cytembena (NSC-104801) in patients with advanced ovarian carcinoma resistant to alkylating agents: brief communication.

J Natl Cancer Inst. 1977 Dec;59(6):1619-20. doi: 10.1093/jnci/59.6.1619.

[Phase II study of etoposide (VP-16-213) in genitourinary tumors. VP-16-213 Genitourinary Study Group].

Gan To Kagaku Ryoho. 1986 Sep;13(9):2772-9.

Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study.

Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2089-92.

Oral VP-16-213 in transitional cell carcinoma of the bladder: a phase II study.口服依托泊苷（VP - 16 - 213）治疗膀胱移行细胞癌：一项II期研究。

Cancer Treat Rep. 1981 Jul-Aug;65(7-8):703-4.

Multicenter Phase II trial of etoposide in refractory small cell lung cancer.

Cancer Treat Rep. 1985 Jan;69(1):127-8.

[A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].

Gan To Kagaku Ryoho. 1986 Jan;13(1):116-21.

引用本文的文献

Oral etoposide for the treatment of recurrent ovarian cancer.

Drugs. 1999;58 Suppl 3:43-9. doi: 10.2165/00003495-199958003-00007.

The podophyllotoxin derivatives VP16-213 and VM26.

Cancer Chemother Pharmacol. 1982;7(2-3):73-80. doi: 10.1007/BF00254525.

[Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].依托泊苷（VP 16-213）——一种具有高抗肿瘤活性的鬼臼毒素衍生物（作者译）

Klin Wochenschr. 1981 Nov 2;59(21):1177-88. doi: 10.1007/BF01721212.

Developing new drugs for ovarian cancer: a challenging task in a changing reality.开发卵巢癌新药：在不断变化的现实中的一项具有挑战性的任务。

J Cancer Res Clin Oncol. 1984;107(2):111-24. doi: 10.1007/BF00399382.

Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer.慢性低剂量口服依托泊苷作为铂类难治性卵巢癌挽救治疗的2期试验。

J Cancer Res Clin Oncol. 1992;119(1):55-7. doi: 10.1007/BF01209489.

Podophyllotoxin derivative VP 16-213.鬼臼毒素衍生物VP 16 - 213

Cancer Chemother Pharmacol. 1979;3(2):71-80. doi: 10.1007/BF00254976.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验